Study Review – MURANO, venetoclax-rituximab in chronic lymphocytic leukaemia

This review is a summary of an individual study; Fixed duration venetoclax-rituximab eradicates minimal residual disease and prolongs survival in patients with chronic lymphocytic leukaemia. The study involved 109 study centres across 20 countries.

Independent commentary is provided by Professor John Seymour, a clinical haematologist and Associate Director of Clinical Research at the Peter MacCallum Centre, and the Director of the integrated Haematology Department of the Peter MacCallum Cancer Centre & the Royal Melbourne Hospital in Melbourne, Australia.


Please login below to download this issue (PDF)